Finance

Lists
Why is OBIO down 6.30%?
Dive Deeper
OBIO:NASDAQ
Orchestra Biomed Holdings Inc
$5.95
-6.30%
(-0.40) 1D
$5.95
0.00% (0.00)
After hours
Closed: Oct 2, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OBIO...
Open
$6.40
High
$6.44
Low
$5.77
Mkt. cap
357.63M
Avg. vol.
335.44K
Volume
421.09K
52-wk high
$6.50
52-wk low
$2.66
EPS
-$1.01
Beta
0.52
Shares outstanding
60.10M
No. of employees
86
Open
$6.40
High
$6.44
Low
$5.77
Mkt. cap
357.63M
Avg. vol.
335.44K
Volume
421.09K
52-wk high
$6.50
52-wk low
$2.66
EPS
-$1.01
Beta
0.52
Shares outstanding
60.10M
No. of employees
86
News stories
From web sources and news partners
About Orchestra Biomed Holdings Inc
CEO-
Employees86
Founded2018
Headquarters-
SectorMedical device
Websiteorchestrabiomed.com
Analyst ratings
Based on 5 analysts giving stock ratings to OBIO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OBIO in the last 3 months.
Highest
Current $5.95
$15.00 (+152.10%)
Average
$11.20 (+88.24%)
Lowest
$10.00 (+68.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yi Chen
H.C. Wainwright
Buy
Reiterated
$10.00
+68.1%
10/02/2026
Madison Elsaadi
B. Riley Securities
Buy
Reiterated
$11.00
+84.9%
10/02/2026
Josh Jennings
TD Cowen
Buy
Reiterated
$15.00
+152.1%
09/25/2026
Marie Thibault
BTIG
Buy
Upgraded
$10.00
+68.1%
09/10/2026
Matthew O'Brien
Piper Sandler
Buy
Reiterated
$10.00
+68.1%
08/11/2026
Unknown Analyst
BTIG
Hold
Maintained
-
-
07/09/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
$10.00
+68.1%
05/18/2026
Matt Miksic
Barclays
Buy
Reiterated
$13.00
+118.5%
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$20.00
+236.1%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
861.00K
30.92M
110.00K
88.00K
Cost of goods sold
49.00K
51.00K
32.00K
25.00K
Cost of revenue
49.00K
51.00K
32.00K
25.00K
Research and development expenses
14.03M
16.82M
15.78M
16.59M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.10M
7.29M
6.37M
5.83M
Operating expense
21.12M
24.11M
22.15M
22.42M
Total operating expenses
21.17M
24.16M
22.19M
22.44M
Operating income
-20.31M
6.75M
-22.08M
-22.36M
Other non operating income
-
254.00K
-376.00K
-517.00K
EBT including unusual items
-20.83M
6.24M
-20.69M
-23.76M
EBT excluding unusual items
-20.83M
6.24M
-22.93M
-23.80M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.83M
6.24M
-20.69M
-23.76M
Net profit margin
-2,419.05%
20.20%
-18,810.00%
-26,994.32%
Earnings per share
-0.40
0.26
-0.33
-0.37
Interest and investment income
-
752.00K
-
-
Interest expense
-515.00K
-1.52M
-480.00K
-927.00K
Net interest expenses
-515.00K
-763.00K
-480.00K
-927.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.23M
6.84M
-21.99M
-22.26M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps